Over 20 years ago, Caroline Acker and a group of volunteers set up a few folding tables and chairs in a parking lot in the Hill District. They handed out clean needles to anyone who asked. Before long, a neighborhood association threatened to call the police, and so Acker and her volunteers packed up to a new location. When it happened again— as it always did— they packed up, and moved again.
Prevention Point Pittsburgh (PPP), a nonprofit organization that provides new syringes, anti-overdose drugs, and other harm reduction services to addicts, found both a home and legal protection in 2001, with the official authorization of the Allegheny County Board of Health. Today, the program operates out of three locations— in Oakland, Perry Hilltop, and the Hill District— and distributes an average of 6,044 needles each week.
As the organization has grown, though, so too, has the opioid and heroin epidemic, and Prevention Point Pittsburgh now finds itself facing almost more demand than it can meet. That’s especially true when it comes to the anti-overdose drug naloxone, which PPP also distributes for free to its participants. According to Overdose Prevention project coordinator Alice Bell, PPP dispensed 866 new prescriptions of naloxone for its participants in 2015. That number accounts for almost half of the total 2,041 prescriptions PPP has provided since 2005.
PPP’s executive director Aaron Arnold attributes this dramatic increase in demand to both the November 2014 passage of Act 139, which granted legal immunity to individuals responding to an overdose, and the remaining barriers to obtaining the drug.
In October 2015, Pa. Governor Tom Wolf and Physician General Rachel Levine signed a standing order allowing anyone in Pennsylvania to get naloxone. However, calls by Pittsburgh Post-Gazette reporters Tuesday to 32 area pharmacies found 16 did not supply Naloxone, and two required a doctor’s prescription for the drug.
“Something we’re seeing is that there’s a lot of variability in participating in that standing order,” Mr. Arnold said. “It depends on the branch you go to, on the person who’s working, and then we see people... who may have a co-pay, and that becomes a barrier, as well.”
Prevention Point Pittsburgh spent about $45,000 of its total budget of about $300,000 on naloxone in 2015. (The organization purchases the intra-muscular brand of naloxone wholesale from medical suppliers for $16 per kit, a price that continues to climb). Though Prevention Point Pittsburgh has been able to provide naloxone to all participants who requested it, it has had to limit the number of community outreach events where volunteers distribute the drug.
PPP receives about 65% of its funding from state and county contracts, and the rest from smaller, often one-time grants and individual donations. It receives no consistent or regular sources of funding specifically for naloxone.
One reason why the organization faces such a large demand, Arnold said, is that it remains the only county approved syringe-exchange program in Southwestern Pennsylvania. Currently, the State’s Controlled Substances, Drugs, Device and Cosmetics Act prohibits carrying syringes intended for the use of drugs. Only two counties, Allegheny and Philadelphia, have authorized needle exchange programs.
Gov. Wolf supports the expansion of programs like Prevention Point Pittsburgh, according to his spokesperson, Jeffrey Sheridan. However, establishing syringe exchange programs elsewhere in Pennsylvania would require either changes to the state law or new regulations on the county level.
For Mr. Arnold, who grew up in Lebanon, Pennslyvania, witnessing classmates, friends, and relatives become addicts, the need for harm-reduction service has always outweighed political challenges.
“It just felt so desperately necessary to me,” he said.
Maia R. Silber: msilber@post-gazette.com
Correction, posted June 17, 2016: In a previous version of the story, job titles for Alice Bell and Aaron Arnold were misidentified.
Read OVERDOSED: How doctors wrote the script for an epidemic. Email the team at overdosed@post-gazette.com, and read the OVERDOSED blog for more on the Post-Gazette’s investigation, readers’ stories, and the latest news about the drug epidemic.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.